Press ReleaseFirst cohort under amended protocol succesfully completes safety evaluation in HOVON 172 MF clinical study of tasquinimod in myelofibrosis
Press ReleaseActive Biotech Strengthens Global Patent Protection for Laquinimod with Patent Grant in Japan
Press ReleaseActive Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis
Press ReleaseEuropean regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON
